Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2003-12-22
2010-02-09
Woodward, Cherie M (Department: 1647)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C424S093200, C424S192100, C424S193100, C424S195110, C435S325000, C536S023100, C536S023500
Reexamination Certificate
active
07659368
ABSTRACT:
Novel chimeric heteromultimer adhesins that bind the ligand of natural heteromultimeric receptors and uses therefor are disclosed. The chimeric molecules of the heteromultimer adhesins comprise an extracellular domain of a heteromultimeric receptor monomer and a multimerization domain for the stable interaction of the chimeric molecules in the adhesin. Specifically disclosed are heteromultimeric adhesins comprising the extracellular domains of ErbB2 and ErbB3 or ErbB2 and ErbB4. The chimeric ErbB heteromultimer adhesins of the present invention are useful as competitive antagonists or agonists of a neuregulin for the treatment of diseases such as various cancers.
REFERENCES:
patent: 4676980 (1987-06-01), Segal et al.
patent: 4892538 (1990-01-01), Aebischer et al.
patent: 5116964 (1992-05-01), Capon et al.
patent: 5225538 (1993-07-01), Capon et al.
patent: 5283187 (1994-02-01), Aebischer et al.
patent: 5336603 (1994-08-01), Capon et al.
patent: 5428130 (1995-06-01), Capon et al.
patent: 5447851 (1995-09-01), Beutler et al.
patent: 5455165 (1995-10-01), Capon et al.
patent: 5514582 (1996-05-01), Capon et al.
patent: 5565335 (1996-10-01), Capon et al.
patent: 5714147 (1998-02-01), Capon et al.
patent: 5726037 (1998-03-01), Bodary et al.
patent: 5726290 (1998-03-01), Bodary et al.
patent: 5731168 (1998-03-01), Carter et al.
patent: 5804396 (1998-09-01), Plowman
patent: 5807706 (1998-09-01), Carter
patent: 5821333 (1998-10-01), Carter et al.
patent: 6117655 (2000-09-01), Capon et al.
patent: WO 89/02922 (1989-04-01), None
patent: WO 91/00360 (1991-01-01), None
patent: WO 94/00140 (1994-01-01), None
patent: WO 94/04690 (1994-03-01), None
patent: WO 95/14930 (1995-06-01), None
patent: WO 95/25795 (1995-09-01), None
patent: WO 95/27061 (1995-10-01), None
Plowman et al., PNAS USA 1990 87:4905-4909.
Lee et al., Cancer Research Jun. 1, 2001; 61:4467-4473.
Bowie et al, 1990, Science 247:1306-1310.
Wells, 1990, Biochemistry 29:8509-8517.
Chen et al., J Biol Chem. Mar. 29, 1996; 271(13):7620-7629.
Sliwkowski et al., J Biol Chem. May 20, 1994; 269(20):14661-14665.
Tzahar et al., J Biol Chem. Oct. 7, 1994; 269((40):25226-25233.
UniProtKB/Swiss-Prot P21860 (ERBB3—HUMAN) (version 10, Nov. 1, 1995).
UniProtKB/Swiss-Prot P04626 (ERBB2—HUMAN) (version 14, Nov. 1, 1995).
Horan et al., (J Biol Chem.Oct. 13, 1995;270(41):24604-8).
Ashkenazi et al., “Protection Against Endotoxic Shock by a Tumor Necrosis Factor Receptor Immunoadhesin”,Proc. Natl. Acad. Sci., 88:10535-10539 (1991).
Banner et al., “Crystal Structure of the Soluble Human 55 kd TNF Receptor-Human TNFβ Complex: Implications for TNF Receptor Activation”,Cell, 73:431-445 (1993).
Beerli et al., “Neu Differentiation Factor Activation of ErbB-3 and ErbB-4 is Cell Specific and Displays a Differential Requirement for ErbB-2”,Molecular&Cellular Biology, 15:6496-6505 (Dec. 1995).
Brennan et al., “Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1fragments”,Science, 229:81-83 (Jul. 1985).
Brown et al., “The Extracellular Domain of the Epidermal Growth Factor Receptor”,European Journal of Biochemistry, 225:223-233 (1994).
Carpenter, “Receptors for Epidermal Growth Factor and Other Polypeptide Mitogens”,Ann. Rev. Biochem., 56:881-914 (1987).
Chamow et al., “Immunoadhesins: Principles and Applications”,Trends in Biotechnology, 14:52-60 (1996).
Chang et al., “Modulation of Growth Factor Receptor Function by Isoform Heterodimerization”,Proc. Natl. Acad. Sci. USA, 93:5947-5952 (1996).
Collesi et al., “A Splicing Variant of the RON Transcript Induces Constitutive Tyrosine Kinase Activity and an Invasive Phenotype”,Molecular&Cellular Biology, 16(10):5518-5526 (1996).
Dietrich et al., “Role of CD3γ in T Cell Receptor Assembly”,Journal of Cell Biology, 132(3):299-310 (1996).
Dietsch et al., “Bispecific Receptor Globulins, Novel Tools for the Study of Cellular Interactions”,Journal of Immunological Methods, 162:123-132 (1993).
Ellison et al., “The nucleotide sequence of a human immunoglobulin Cγ1gene”,Nucleic Acids Research, 10(13):4071-4079 (1982).
Fendly et al., “Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor of HER2
eu Gene Product”,Cancer Research, 50:1550-1558 (Mar. 1, 1990).
Ganong,Review of Medical Physiology, 17th edition, Norwalk, Connecticut:Appleton & Lange, p. 580 (1995).
Gascoigne et al., “Secretion of a Chimeric T-cell Receptor-Immunoglobulin Protein”,Proc. Natl. Acad. Sci. USA, 84:2936-2940 (1987).
Gorman et al., “Transient Production of Proteins Using an Adenovirus Transformed Cell Line”,DNA Prot. Eng. Tech., 2(1):3-10 (1990).
Gruber et al., “Efficient Tumor Cell Lysis Mediated by a Bispecific Single Chain Antibody Expressed inEscherichia coli”, Journal of Immunology, 152:5368-5374 (1994).
Hollinger et al., “Diabodies: Small bivalent and bispecific antibody fragments”,Proc. Natl. Acad. Sci. USA, 90:6444-6448 (Jul. 1993).
Horan et al., “Binding of Neu Differentiation Factor with the Extracellular Domain of Her2 and Her3”,Journal of Biological Chemistry, 270(41):24604-24608 (1995).
Kainu et al., “The Dioxin Receptor and its Nuclear Translocator (Arnt) in the Rat Brain”,Neuroreport, 6:2557-2560 (1995).
Karunagaran et al., “ErbB-2 is a Common Auxiliary Subunit of NDF and EGF Receptors: Implications for Breast Cancer”,EMBO Journal, 15(2):254-264 (1996).
Kendall et al., “Identification of a Natural Soluble Form of the Vascular Endothelial Growth Factor Receptor, FLT-1, and Its Heterodimerization with KDR”,Biochem. &Biophys. Res. Comm., 226:324-328 (1996).
King et al., “Ligand-independent tyrosine phosphorylation of EGF receptor and the erbB-2
eu proto-oncogene product is induced by hyperosmotic shock”,Oncogene, 4(1):13-18 (Jan. 1989).
Kishimoto et al., “Cytokine Signal Transduction”,Cell, 76:253-262 (Jan. 28, 1994).
Kokai et al., “Synergistic Interaction of p185c-neu and the EGF Receptor Leads to Transformation of Rodent Fibroblasts”,Cell, 58:287-292 (1989).
Kostelny et al., “Formation of a Bispecific Antibody by the Use of Leucine Zippers”,Journal of Immunology, 148(5):1547-1553 (1992).
Lala et al., “Activation of Specific RXR Heterodimers by an Antagonist of RXR Homodimers”,Nature, 383:450-453 (1996).
Lemke, “Neuregulins in Development”,Molecular and Cellular Neuroscience, 7:247-262 (1996).
Levi et al., “The functional characteristics of Schwann Cells cultured from human peripheral nerve after transplantation into a gap within the rat sciatic nerve”,J. Neuroscience, 14(3):1309-1319 (1994).
Levi et al., “The influence of Heregulins on Human Schwann Cell Proliferation”,J. Neuroscience, 15(2):1329-1340 (Feb. 1995).
Lewis et al., “Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness”,Cancer Research, 56:1457-1465 (1996).
Li et al., “Identification of Gas6 as a Growth Factor for Human Schwann Cells”,The Journal of Neuroscience, 16(6):2012-2019 (Mar. 15, 1996).
Marsters et al., “Interferon γ Signals Via a High-Affinity Multisubunit Receptor Complex that Contains Two Types of Polypeptide Chain”,Proc. Natl. Acad. Sci. USA, 92:5401-5405 (1995).
McBain et al., “N-Methyl-D-Aspartic Acid Receptor Structure and Function”,Physiological Reviews, 74(3):723-760 (Jul. 1994).
Meyer & Birchmeier, “Distinct isoforms of neuregulin are expressed in mesenchymal and neuronal cells during mouse development”,Proc. Natl. Acad. Sci., 91:1064-1068 (1994).
Morrissey et al., “Axon-induced mitogenesis of human Schwann c
Fitzpatrick Vincent Danial
Sliwkowski Mark
Vandlen Richard L.
Arnold & Porter LLP
Bernhardt Jeffery P.
Genentech Inc.
Woodward Cherie M
LandOfFree
ErbB2 and ErbB3 chimeric heteromultimer adhesins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with ErbB2 and ErbB3 chimeric heteromultimer adhesins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and ErbB2 and ErbB3 chimeric heteromultimer adhesins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4176477